Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Protalix BioTherapeutics, Inc. PLX

Healthcare  —  Biotechnology
2.72 (0.03) (1.09%) as of 25 Sep
Market cap
$221.6M
P/E
11.3×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Protalix BioTherapeutics, Inc. (PLX) Business Profile

Updated before January 2025

Company Overview

Protalix BioTherapeutics, Inc. (PLX) is a biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins. The company was founded in 1993 and is headquartered in Carmiel, Israel. Protalix is renowned for its proprietary ProCellEx® plant cell-based protein expression system, which serves as the foundation for its innovative product pipeline. The company’s leadership team includes experienced professionals in biotechnology and pharmaceuticals, with Dror Bashan serving as the President and Chief Executive Officer. Under his leadership, Protalix has continued to expand its product portfolio and strengthen its position in the biopharmaceutical industry.

Core Business Segments

Protalix focuses on the development of therapeutic proteins for the treatment of rare and chronic diseases. Its core business segments include:

1. Enzyme Replacement Therapies (ERTs)

Protalix’s flagship products fall under the category of enzyme replacement therapies, which are designed to treat rare genetic disorders. Key products include:

  • Elelyso® (taliglucerase alfa): Approved for the treatment of Gaucher disease, Elelyso is the first plant cell-expressed recombinant therapeutic protein to receive regulatory approval.
  • PRX-102 (pegunigalsidase alfa): A novel ERT for the treatment of Fabry disease, currently under regulatory review and clinical trials.

2. Pipeline Products

Protalix is actively developing additional therapeutic proteins targeting unmet medical needs. These include:

  • PRX-110: A treatment for cystic fibrosis.
  • PRX-115: A potential therapy for gout.
  • PRX-119: A long-acting anti-inflammatory treatment.

3. Licensing and Partnerships

Protalix collaborates with global pharmaceutical companies to commercialize its products. For instance, Elelyso is marketed outside of Israel by Pfizer under a licensing agreement.

Business Model

Protalix operates on a hybrid business model that integrates in-house research and development with strategic partnerships. The company generates revenue through:

  • Product Sales: Direct sales of Elelyso in Israel and royalties from global sales by Pfizer.
  • Collaborations and Licensing Agreements: Protalix partners with pharmaceutical companies to co-develop and commercialize its products, sharing both risks and rewards.
  • Research Grants: The company occasionally receives funding from governmental and non-governmental organizations to support its R&D efforts.

Protalix’s ProCellEx® platform allows for cost-effective production of therapeutic proteins, giving it a competitive edge in terms of scalability and affordability.

Strategic Direction

Protalix is focused on expanding its product pipeline and entering new markets. Key strategic goals include:

  • Regulatory Approvals: Securing FDA and EMA approvals for PRX-102 and other pipeline products.
  • Geographic Expansion: Increasing its presence in emerging markets to tap into unmet medical needs.
  • Sustainability Goals: Leveraging its plant-based production system to minimize environmental impact and reduce manufacturing costs.
  • Innovation: Investing in R&D to develop next-generation therapies for rare and chronic diseases.

Competitive Landscape

Protalix operates in a highly competitive biopharmaceutical sector. Key competitors include:

  • Sanofi Genzyme: A leader in enzyme replacement therapies.
  • Shire (now part of Takeda): Known for its extensive portfolio of rare disease treatments.
  • Amicus Therapeutics: Focused on developing therapies for rare metabolic diseases.
  • BioMarin Pharmaceutical: Specializes in treatments for genetic disorders.

Protalix differentiates itself through its proprietary ProCellEx® platform, which offers cost advantages and scalability compared to traditional mammalian cell-based systems.

Risk Factors

Protalix faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for pipeline products.
  • Market Dependence: Heavy reliance on Elelyso and PRX-102 for revenue generation.
  • Supply Chain Disruptions: Potential challenges in sourcing raw materials or scaling up production.
  • Competition: Intense competition from established players in the biopharmaceutical industry.
  • Financial Risks: Dependence on external funding and partnerships to sustain R&D activities.

Recent Developments

Protalix has made significant progress in recent years, including:

  • PRX-102 Regulatory Review: The company submitted a Biologics License Application (BLA) for PRX-102 to the FDA and is awaiting approval.
  • Clinical Trials: Advancing late-stage clinical trials for PRX-102 and other pipeline products.
  • Partnership with Chiesi Farmaceutici: Collaborating with Chiesi to commercialize PRX-102 in global markets.
  • COVID-19 Impact: Implementing measures to ensure business continuity and mitigate supply chain disruptions during the pandemic.

Investment Considerations

Strengths:

  • Proprietary ProCellEx® platform offering cost and scalability advantages.
  • Strong pipeline of innovative therapies targeting unmet medical needs.
  • Strategic partnerships with global pharmaceutical companies.
  • Established track record with regulatory approvals for Elelyso.

Risks:

  • Dependence on a limited number of products for revenue.
  • Regulatory and clinical trial uncertainties.
  • Competitive pressures from larger biopharmaceutical companies.
  • Financial constraints due to high R&D costs.

Conclusion

Protalix BioTherapeutics, Inc. is a pioneering biopharmaceutical company with a strong focus on developing innovative therapies for rare and chronic diseases. Its proprietary ProCellEx® platform and strategic partnerships position it as a competitive player in the industry. While the company faces challenges such as regulatory risks and market dependence, its robust pipeline and commitment to innovation provide a solid foundation for future growth. Protalix is well-positioned to capitalize on emerging opportunities in the biopharmaceutical sector, making it an attractive option for investors seeking exposure to the rare disease market.